about
Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging.Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsivenessNY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity.Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models.Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice.By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.Tumor-targeting Salmonella typhimurium A1-R arrests growth of breast-cancer brain metastasis.Traditional Chinese medicine herbal mixture LQ arrests FUCCI-expressing HeLa cells in G₀/G₁ phase in 2D plastic, 2.5D Matrigel, and 3D Gelfoam culture visualized with FUCCI imaging.Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice.Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma.Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapyTumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse modelsWt p53 impairs response to chemotherapy: make lemonade to spare normal cellsEradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus.Target for cancer therapy: proliferating cells or stem cells.Fibulin-5 function during tumorigenesis.Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models.Therapeutic efficacy of tumor-targeting Salmonella typhimurium A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse modelsAdjuvant treatment with tumor-targeting Salmonella typhimurium A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model.Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse modelsAdenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models.Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy.Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse modelFluorescence-guided surgery of a highly-metastatic variant of human triple-negative breast cancer targeted with a cancer-specific GFP adenovirus prevents recurrence.Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models.Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-cateninReconstitution of a metastatic-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis.Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model.Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging.Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro.
P2860
Q27311397-22C44F04-3397-4810-A519-BA7B42CFB997Q33829258-E8A93B01-03EB-40A4-BA69-58C5BA47125DQ33952918-65045D4A-4543-49C5-A1D7-5D2C2E1937A0Q34221846-1806E741-8015-4437-9F78-0FE5951F8FDEQ34483751-275A983C-D8E6-4F42-BB6B-5392ECE057FCQ35067893-6D1BEA9D-00DF-4DE6-A648-D7CABE1EB7AFQ35172310-B7658328-CBC1-47E5-9642-A72D53780105Q35273614-AB8D0FB2-CB98-4402-BC82-3CD3A78A4436Q35550049-C4CC24C5-334B-44ED-AC3F-4E8B874B06E1Q35741664-55AD32C1-3975-42FE-9A0B-119DFE2A142EQ35793808-772DD183-2FD0-4B10-9B32-2B304816770FQ35955227-8388376E-59BB-414F-8F20-0C85F774CCE8Q35987427-451E1A8E-2E66-4043-A6DF-C478092A1DDAQ36125108-93D55011-164F-47D7-BB28-4F20755C1FCFQ36189385-8B423276-B359-453B-B6D6-6E25A7302DFFQ36198088-FD30838C-47EF-4175-AB15-0F177E664D81Q36234051-31C582CA-F0A9-44AB-8ACD-F993F837AC8DQ36240189-99755D65-3A13-413D-9598-8A25FB54F698Q36343524-3B848EDB-9612-4EFC-9993-25F6C5812F9CQ36429377-435AF145-9D2E-40BB-B353-C31EC2FF8826Q36544572-56F975E4-2202-4913-B49D-3D32A4920A7FQ36544581-62F443CA-B9AE-4F08-971E-7A4533342100Q36561606-B551F1AE-323E-4045-AB15-7F229BD99BF6Q37109728-CA9EE293-70AE-4870-9703-877F333B6435Q37109813-E69039E9-E22B-4E73-9BEA-EB0BFAF2CB7EQ37118741-80011B0E-73D5-49AF-B798-1B895941EE89Q37362834-296392F3-D809-4F2F-B538-95F321239C0CQ37376492-718259E7-BD05-4BAE-8E08-6ED0B2764113Q37565198-79A19F45-4172-412F-A6F8-C5F0B2BFAB0FQ37687682-1CB94195-CC1B-4ABD-A6F4-6CD3D7987F51Q37687695-F75086E6-7C99-4D0D-B837-EF0E0E830DDDQ37688996-4F42680C-E355-4AC9-9F6F-C1126CA609A9Q37699156-C9743D9F-7BDC-480E-A95B-BF327AD90CFAQ37699363-78C910C6-CE91-47C3-937B-22CCDB7DDE91Q37718335-949B9633-78DD-4ECF-9810-D826EE6D3CA4Q37741870-3BCADBCA-EF3B-4AFA-80B0-0D7D85E032ADQ38706171-8AA3A0A7-5E53-4A98-81F1-9B1164CA0876Q39057954-B1E0D271-E7C7-47DA-B8D8-791635F70C4DQ39065706-1C8EDDD3-EB26-4325-91C3-A44E0F1E6333Q40854586-59EA9FFA-198C-428A-A792-5F0DE44219E6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tissue-selective therapy of cancer.
@ast
Tissue-selective therapy of cancer.
@en
type
label
Tissue-selective therapy of cancer.
@ast
Tissue-selective therapy of cancer.
@en
prefLabel
Tissue-selective therapy of cancer.
@ast
Tissue-selective therapy of cancer.
@en
P2860
P356
P1476
Tissue-selective therapy of cancer.
@en
P2093
M V Blagosklonny
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601256
P407
P577
2003-10-01T00:00:00Z
2003-10-06T00:00:00Z